{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T04:21:01Z","timestamp":1794543661981,"version":"4.9.1"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Pilomatrix-like high-grade endometrial carcinoma (PiMHEC) is a rare and aggressive variant of endometrial carcinoma often misdiagnosed due to overlapping features with other high-grade malignancies. This study characterizes its clinicopathologic, immunophenotypic, and molecular features to establish key diagnostic criteria and propose a standardized terminology. Ten tumors were analyzed using histopathologic examination, immunohistochemistry, and next-generation sequencing. All but 1 tumor exhibited both low-grade endometrioid and high-grade basaloid components, the latter characterized by either geographic or comedo-type necrosis and shadow cells. Although shadow cells are a hallmark feature, they may be focal or absent, necessitating careful evaluation. High-grade areas consistently showed ER and PR negativity with diffuse nuclear \u03b2-catenin staining, correlating with CTNNB1 exon 3 mutations in all tumors. Identical CTNNB1 mutations in spatially distinct tumor components suggest a clonal progression from a low-grade precursor. Additional mutations in ARID1A, PTEN, and PIK3CA were identified. Clinically, PiMHEC exhibited aggressive behavior, with 7 patients experiencing recurrence and 1 succumbing to the disease within 9 months. Metastatic sites included the lungs, liver, lymph nodes, and abdominal wall. PD-L1 expression in 4 tumors suggests potential responsiveness to immune checkpoint inhibitors, whereas low-level HER2 expression (1+ to 2+) in 5 tumors raises the possibility of HER2-targeted therapies. Folate receptor alpha was not expressed in any tumor. In conclusion, PiMHEC is a distinct and highly aggressive endometrial carcinoma with unique histopathologic and molecular features that differentiate it from high-grade endometrioid and other high-grade endometrial cancers including squamous cell carcinoma in rare situations. Its key diagnostic features include high-grade basaloid tumor cells associated with shadow cells, tumor necrosis, and diffuse nuclear \u03b2-catenin staining. To improve diagnostic accuracy and reduce ambiguity, we propose adopting \u201cpilomatrix-like high-grade endometrial carcinoma\u201d as a standardized term.<\/jats:p>","DOI":"10.1097\/pas.0000000000002402","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T10:00:20Z","timestamp":1744192820000},"page":"818-829","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Pilomatrix-like High-grade Endometrial Carcinoma"],"prefix":"10.1097","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2402-4774","authenticated-orcid":false,"given":"Feng","family":"Zhou","sequence":"first","affiliation":[{"name":"Departments of Pathology, The International Peace Maternal and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University"},{"name":"Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Qin","sequence":"additional","affiliation":[{"name":"Departments of Pathology, The International Peace Maternal and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University"},{"name":"Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suming","family":"Huang","sequence":"additional","affiliation":[{"name":"Departments of Pathology, The International Peace Maternal and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University"},{"name":"Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanrun","family":"Lin","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Departments of Pathology, The International Peace Maternal and Child Health Hospital, School of Medicine, Shanghai Jiao Tong University"},{"name":"Shanghai Key Laboratory of Embryo Original Diseases, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinita","family":"Parkash","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale School of Medicine, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Pathology"},{"name":"Obstetrics and Gynecology"},{"name":"Harold C. Simon Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"R1-20250728","first-page":"17","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"R2-20250728","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.3802\/jgo.2023.34.e85","article-title":"Endometrial Cancer Staging Subcommittee FWsCC: FIGO staging of endometrial cancer: 2023","volume":"34","author":"Berek","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"R4-20250728","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/PGP.0000000000000859","article-title":"Pilomatrix-like high-grade endometrioid carcinoma is a morphologically and immunophenotypically distinct entity and may show mismatch repair deficiency","volume":"42","author":"Arciuolo","year":"2023","journal-title":"Int J Gynecol Pathol"},{"key":"R5-20250728","article-title":"High-grade endometrial carcinomas with solid basaloid morphology and geographic necrosis lacking definitive pilomatrix-like features: clinicopathologic characteristics including aggressive behavior and novel molecular events","author":"Carlson","year":"2024","journal-title":"Int J Gynecol Pathol"},{"key":"R6-20250728","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1097\/PGP.0000000000000942","article-title":"Endometrioid adenocarcinoma resembling cutaneous pilomatrix carcinoma: a case report of an aggressive neoplasm in a young woman with diffusely aberrant beta-catenin expression and associated morular metaplasia and atypical polypoid adenomyoma-type change","volume":"42","author":"Keane","year":"2023","journal-title":"Int J Gynecol Pathol"},{"key":"R7-20250728","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/PGP.0000000000000775","article-title":"FIGO grade 3 endometrioid adenocarcinomas with diffusely aberrant beta-catenin expression: an aggressive subset resembling cutaneous pilomatrix carcinomas","volume":"41","author":"Weisman","year":"2022","journal-title":"Int J Gynecol Pathol"},{"key":"R8-20250728","first-page":"67","article-title":"An expanded series of pilomatrix-like high-grade endometrioid carcinoma (PiMHEC), including both MMR deficient and MMR proficient cases","volume":"43","author":"Xu","year":"2024","journal-title":"Int J Gynecol Pathol"},{"key":"R9-20250728","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaad.2014.02.042","article-title":"Pilomatrix carcinoma: 13 new cases and review of the literature with emphasis on predictors of metastasis","volume":"71","author":"Herrmann","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"R10-20250728","doi-asserted-by":"crossref","first-page":"1442441","DOI":"10.1155\/2022\/1442441","article-title":"The role of CTNNB1 in endometrial cancer","volume":"2022","author":"Ledinek","year":"2022","journal-title":"Dis Markers"},{"key":"R11-20250728","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PGP.0000000000000583","article-title":"Clinicopathologic and immunohistochemical correlates of CTNNB1 mutated endometrial endometrioid carcinoma","volume":"39","author":"Costigan","year":"2020","journal-title":"Int J Gynecol Pathol"},{"key":"R12-20250728","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1186\/s40425-019-0768-9","article-title":"The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors","volume":"7","author":"Davis","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R13-20250728","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/PAS.0000000000002030","article-title":"HER2 IHC expression and gene amplification in p53-aberrant high-grade endometrial endometrioid carcinoma suggests that this population may benefit from HER2 testing and targeted therapy","volume":"47","author":"Joehlin-Price","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"R14-20250728","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/PGP.0b013e3182774562","article-title":"Expression of folate receptor-alpha (FRA) in gynecologic malignancies and its relationship to the tumor type","volume":"32","author":"O\u2019Shannessy","year":"2013","journal-title":"Int J Gynecol Pathol"},{"key":"R15-20250728","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00428-021-03176-5","article-title":"Clinicopathological features and prognostic significance of CTNNB1 mutation in low-grade, early-stage endometrial endometrioid carcinoma","volume":"479","author":"Ruz-Caracuel","year":"2021","journal-title":"Virchows Arch"},{"key":"R16-20250728","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/path.5375","article-title":"p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies","volume":"250","author":"Singh","year":"2020","journal-title":"J Pathol"},{"key":"R17-20250728","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00428-020-03007-z","article-title":"ESGO\/ESTRO\/ESP Guidelines for the management of patients with endometrial carcinoma","volume":"478","author":"Concin","year":"2021","journal-title":"Virchows Arch"},{"key":"R18-20250728","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"R19-20250728","doi-asserted-by":"crossref","first-page":"11623","DOI":"10.2147\/CMAR.S279888","article-title":"Dedifferentiated endometrioid carcinomas with neuroendocrine differentiation: a clinicopathological and immunohistochemical study of three cases","volume":"12","author":"Zhou","year":"2020","journal-title":"Cancer Manag Res"},{"key":"R20-20250728","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/PAS.0000000000000633","article-title":"Neuroendocrine carcinoma of the endometrium: a clinicopathologic study of 25 cases","volume":"40","author":"Pocrnich","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R21-20250728","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1159\/000490491","article-title":"Shadow cell differentiation: a comparative analysis of modes of cell death with apoptosis and epidermal\/trichilemmal keratinization","volume":"5","author":"Nakamura","year":"2018","journal-title":"Dermatopathology (Basel)"},{"key":"R22-20250728","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/PGP.0000000000000888","article-title":"CTNNB1 -mutated high-grade endometrioid carcinoma with extensive squamous and shadow cell differentiation can mimic pilomatrix carcinoma","volume":"42","author":"Mendoza","year":"2023","journal-title":"Int J Gynecol Pathol"},{"key":"R23-20250728","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.humpath.2013.06.020","article-title":"Frequent beta-catenin gene mutations in atypical polypoid adenomyoma of the uterus","volume":"45","author":"Takahashi","year":"2014","journal-title":"Hum Pathol"},{"key":"R24-20250728","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1097\/PAS.0000000000001934","article-title":"Morules but not squamous differentiation are a reliable indicator of CTNNB1 (beta-catenin) mutations in endometrial carcinoma and precancers","volume":"46","author":"Niu","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"R25-20250728","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3390\/diagnostics12123146","article-title":"Pilomatrix-like high-grade endometrioid carcinoma of the ovary: case report, literature review, and differential diagnosis","volume":"12","author":"Santoro","year":"2022","journal-title":"Diagnostics (Basel)"},{"key":"R26-20250728","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2024.01.048","article-title":"Human epidermal growth factor receptor-2 (HER2) expression in FIGO3 high-grade endometrial endometrioid carcinoma: Clinicopathologic characteristics and future directions","volume":"185","author":"Abada","year":"2024","journal-title":"Gynecol Oncol"},{"key":"R27-20250728","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/s41379-021-00997-2","article-title":"Histopathologic features and molecular genetic landscape of HER2-amplified endometrial carcinomas","volume":"35","author":"Ross","year":"2022","journal-title":"Mod Pathol"},{"key":"R28-20250728","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1093\/ajcp\/aqad155","article-title":"Pilomatrix-like breast carcinoma: a mammary analog of pilomatrix-like high-grade endometrioid carcinoma (PiMHEC)","volume":"161","author":"Xu","year":"2024","journal-title":"Am J Clin Pathol"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002402","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T11:00:12Z","timestamp":1753700412000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000002402"}},"subtitle":["An Underdiagnosed Entity With Aggressive Clinicopathologic Features"],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":27,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000002402","relation":{},"ISSN":["0147-5185","1532-0979"],"issn-type":[{"value":"0147-5185","type":"print"},{"value":"1532-0979","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]}}}